IgG4-related disease: Clinical and laboratory features in one hundred twenty-five patients

Arthritis and Rheumatology

Volumn 67, Issue 9, 2015, Pages 2466-2475

  Wallace, Zachary S ^a   Deshpande, Vikram ^a,b   Mattoo, Hamid ^c   Mahajan, Vinay S ^c   Kulikova, Maria ^c   Pillai, Shiv ^b,c   Stone, John H ^a,b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; C REACTIVE PROTEIN; COMPLEMENT; CYCLOPHOSPHAMIDE; GLUCOCORTICOID; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2; IMMUNOGLOBULIN G3; IMMUNOGLOBULIN G4; METHOTREXATE; MYCOPHENOLATE MOFETIL; RITUXIMAB; TAMOXIFEN; IMMUNOGLOBULIN G;

ADULT; AGE; AGED; ARTICLE; AUTOIMMUNE PANCREATITIS; BILIARY STENT; CLINICAL EVALUATION; CLINICAL FEATURE; COHORT ANALYSIS; COMPARATIVE STUDY; COMPLEMENT BLOOD LEVEL; CONTROLLED STUDY; CORTICOSTEROID THERAPY; DISEASE ACTIVITY; DISEASE COURSE; DISEASE DURATION; DISEASE SEVERITY; DRUG TREATMENT FAILURE; EAR NOSE THROAT SURGERY; EOSINOPHIL COUNT; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; FLOW CYTOMETRY; HUMAN; HYPOCOMPLEMENTEMIA; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOGLOBULIN G4 RELATED DISEASE; KIDNEY DISEASE; LYMPH NODE BIOPSY; LYMPHADENOPATHY; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; ONSET AGE; ORBIT DISEASE; PANCREAS SURGERY; PATIENT HISTORY OF SURGERY; PATIENT HISTORY OF THERAPY; PLASMABLAST; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; REMISSION; RETROPERITONEAL FIBROSIS; SCORING SYSTEM; TREATMENT OUTCOME; TREATMENT RESPONSE; UPREGULATION; URETERAL STENTING; AUTOIMMUNE DISEASES; CYTOLOGY; EOSINOPHIL; IMMUNOLOGY; LEUKOCYTE COUNT; MIDDLE AGED; PATHOPHYSIOLOGY; PLASMA CELL; RETROSPECTIVE STUDY; VERY ELDERLY; YOUNG ADULT;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; AUTOIMMUNE DISEASES; COHORT STUDIES; EOSINOPHILS; FEMALE; FLOW CYTOMETRY; GLUCOCORTICOIDS; HUMANS; IMMUNOGLOBULIN G; LEUKOCYTE COUNT; MALE; MIDDLE AGED; PLASMA CELLS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84940103747     PISSN: 23265191     EISSN: 23265205     Source Type: Journal    
DOI: 10.1002/art.39205     Document Type: Article

References (42)

1. Stone JH, Zen Y, Deshpande V., IgG4-related disease. N Engl J Med 2012; 366: 539-51.
2. Kamisawa T, Funata N, Hayashi Y, Eishi Y, Koike M, Tsuruta K, et al., A new clinicopathological entity of IgG4-related autoimmune disease. J Gastroenterol 2003; 38: 982-4.
3. Hamano H, Kawa S, Horiuchi A, Unno H, Furuya N, Akamatsu T, et al., High serum IgG4 concentrations in patients with sclerosing pancreatitis. N Engl J Med 2001; 344: 732-8.
4. Kamisawa T, Zen Y, Pillai S, Stone J., IgG4-related disease. Lancet 2015; 385: 1460-71.
5. Guma M, Firestein GS., IgG4-related diseases. Best Pract Res Clin Rheumatol 2012; 26: 425-38.
6. Ebbo M, Daniel L, Pavic M, Seve P, Hamidou M, Andres E, et al., IgG4-related systemic disease: features and treatment response in a French cohort: results of a multicenter registry. Medicine (Baltimore) 2012; 91: 49-56.
7. Zen Y, Nakanuma Y., IgG4-related disease: a cross-sectional study of 114 cases. Am J Surg Pathol 2010; 34: 1812-9.
8. Chen H, Lin W, Wang Q, Wu Q, Wang L, Fei Y, et al., IgG4-related disease in a Chinese cohort: a prospective study. Scand J Rheumatol 2014; 43: 70-4.
9. Deshpande V, Zen Y, Chan JK, Yi EE, Sato Y, Yoshino T, et al., Consensus statement on the pathology of IgG4-related disease. Mod Pathol 2012; 25: 1181-92.
10. Carruthers M, Khosroshahi A, Augustin T, Deshpande V, Stone J., Diagnostic utility of serum IgG4 concentrations in IgG4-related disease. Ann Rheum Dis 2015; 74: 14-8.
11. Wallace ZS, Mattoo H, Carruthers M, Mahajan VS, Della Torre E, Lee H, et al., Plasmablasts as a biomarker for IgG4-related disease, independent of serum IgG4 concentrations. Ann Rheum Dis 2015; 74: 190-5.
12. Mahajan VS, Mattoo H, Deshpande V, Pillai SS, Stone JH., IgG4-related disease. Annu Rev Pathol 2014; 9: 315-47.
13. Mattoo H, Mahajan VS, Della-Torre E, Sekigami Y, Carruthers M, Wallace ZS, et al., De novo oligoclonal expansions of circulating plasmablasts in active and relapsing IgG-related disease. J Allergy Clin Immunol 2014; 134: 679-87.
14. Matsubayashi H, Sawai H, Kimura H, Yamaguchi Y, Tanaka M, Kakushima N, et al., Characteristics of autoimmune pancreatitis based on serum IgG4 level. Dig Liver Dis 2011; 43: 731-5.
15. Ohta N, Kurakami K, Ishida A, Furukawa T, Saito F, Kakehata S, et al., Clinical and pathological characteristics of IgG4-related sclerosing sialadenitis. Laryngoscope 2012; 122: 572-7.
16. Kuruma S, Kamisawa T, Tabata T, Hara S, Fujiwara T, Kuwata G, et al., Clinical characteristics of patients with autoimmune pancreatitis with or without Mikulicz's disease and Mikulicz's disease alone. Gut Liver 2013; 7: 96-9.
17. Saeki T, Nishi S, Imai N, Ito T, Yamazaki H, Kawano M, et al., Clinicopathological characteristics of patients with IgG4-related tubulointerstitial nephritis. Kidney Int 2010; 78: 1016-23.
18. Patel H, Khalili K, Kyoung KT, Yazdi L, Lee E, May G, et al., IgG4 related disease-a retrospective descriptive study highlighting Canadian experiences in diagnosis and management. BMC Gastroenterol 2013; 13: 168.
19. Takuma K, Kamisawa T, Anjiki H, Egawa N, Igarashi Y., Metachronous extrapancreatic lesions in autoimmune pancreatitis. Intern Med 2010; 49: 529-33.
20. Takahashi H, Yamamoto M, Tabeya T, Suzuki C, Naishiro Y, Shinomura Y, et al., The immunobiology and clinical characteristics of IgG4 related diseases. J Autoimmun 2012; 39: 93-6.
21. Masaki Y, Dong L, Kurose N, Kitagawa K, Morikawa Y, Yamamoto M, et al., Proposal for a new clinical entity, IgG4-positive multiorgan lymphoproliferative syndrome: analysis of 64 cases of IgG4-related disorders. Ann Rheum Dis 2009; 68: 1310-5.
22. Yamamoto M, Yajima H, Takahashi H, Yokoyama Y, Ishigami K, Shimizu Y, et al., Everyday clinical practice in IgG4-related dacryoadenitis and/or sialadenitis: results from the SMART database. Mod Rheumatol 2015; 25: 199-204.
23. Khosroshahi A, Carruthers MN, Deshpande V, Unizony S, Bloch DB, Stone JH., Rituximab for the treatment of IgG4-related disease: lessons from 10 consecutive patients. Medicine (Baltimore) 2012; 91: 57-66.
24. Khosroshahi A, Bloch DB, Deshpande V, Stone JH., Rituximab therapy leads to rapid decline of serum IgG4 levels and prompt clinical improvement in IgG4-related systemic disease. Arthritis Rheum 2010; 62: 1755-62.
25. Carruthers MN, Stone JH, Deshpande V, Khosroshahi A., Development of an IgG4-RD Responder Index. Int J Rheumatol 2012; 2012: 259408.
26. Khosroshahi A, Cheryk LA, Carruthers MN, Edwards JA, Bloch DB, Stone JH., Spuriously low serum IgG4 concentrations caused by the prozone phenomenon in patients with IgG4-related disease. Arthritis Rheumatol 2014; 66: 213-7.
27. Okazaki K, Uchida K, Ikeura T, Takaoka M., Current concept and diagnosis of IgG4-related disease in the hepato-bilio-pancreatic system. J Gastroenterol 2013; 48: 303-14.
28. Kawa S, Ito T, Watanabe T, Maruyama M, Hamano H, Maruyama M, et al., The utility of serum IgG4 concentrations as a biomarker. Int J Rheumatol 2012; 2012: 198314.
29. Kaji R, Takedatsu H, Okabe Y, Ishida Y, Sugiyama G, Yonemoto K, et al., Serum immunoglobulin G4 associated with number and distribution of extrapancreatic lesions in type 1 autoimmune pancreatitis patients. J Gastroenterol Hepatol 2012; 27: 268-72.
30. Hart PA, Kamisawa T, Brugge WR, Chung JB, Culver EL, Czako L, et al., Long-term outcomes of autoimmune pancreatitis: a multicentre, international analysis. Gut 2013; 62: 1771-6.
31. Sandanayake NS, Church NI, Chapman MH, Johnson GJ, Dhar DK, Amin Z, et al., Presentation and management of post-treatment relapse in autoimmune pancreatitis/immunoglobulin G4-associated cholangitis. Clin Gastroenterol Hepatol 2009; 7: 1089-96.
32. Kamisawa T, Shimosegawa T, Okazaki K, Nishino T, Watanabe H, Kanno A, et al., Standard steroid treatment for autoimmune pancreatitis. Gut 2009; 58: 1504-7.
33. Kanno A, Nishimori I, Masamune A, Kikuta K, Hirota M, Kuriyama S, et al., Nationwide epidemiological survey of autoimmune pancreatitis in Japan. Pancreas 2012; 41: 835-9.
34. Hart PA, Topazian MD, Witzig TE, Clain JE, Gleeson FC, Klebig RR, et al., Treatment of relapsing autoimmune pancreatitis with immunomodulators and rituximab: the Mayo Clinic experience. Gut 2013; 62: 1607-15.
35. Saeki T, Kawano M, Mizushima I, Yamamoto M, Wada Y, Nakashima H, et al., The clinical course of patients with IgG4-related kidney disease. Kidney Int 2013; 84: 826-33.
36. Takuma K, Kamisawa T, Tabata T, Inaba Y, Egawa N, Igarashi Y., Short-term and long-term outcomes of autoimmune pancreatitis. Eur J Gastroenterol Hepatol 2011; 23: 146-52.
37. Khosroshahi A, Wallace ZS, Crowe JL, Akamizu T, Azumi A, Carruthers MN, et al., International Consensus Guidance Statement on the Management and Treatment of IgG4-Related Disease. Arthritis Rheumatol 2015; 67:1688-99.
38. Deshpande V, Chicano S, Finkelberg D, Selig MK, Mino-Kenudson M, Brugge WR, et al., Autoimmune pancreatitis: a systemic immune complex mediated disease. Am J Surg Pathol 2006; 30: 1537-45.
39. Nirula A, Glaser SM, Kalled SL, Taylor FR., What is IgG4? A review of the biology of a unique immunoglobulin subtype. Curr Opin Rheumatol 2011; 23: 119-24.
40. Van de Stadt LA, de Vrieze H, Derksen NI, Brouwer M, Wouters D, van Schaardenburg D, et al., Antibodies to IgG4 hinge can be found in rheumatoid arthritis patients during all stages of disease and may exacerbate chronic antibody-mediated inflammation. Arthritis Rheumatol 2014; 66: 1133-40.
41. Muraki T, Hamano H, Ochi Y, Komatsu K, Komiyama Y, Arakura N, et al., Autoimmune pancreatitis and complement activation system. Pancreas 2006; 32: 16-21.
42. Tsuboi H, Nakai Y, Iizuka M, Asashima H, Hagiya C, Tsuzuki S, et al., DNA microarray analysis of labial salivary glands in IgG4-related disease: comparison with Sjögren's syndrome. Arthritis Rheumatol 2014; 66: 2892-9.